ACRES Commercial Realty logo

ACRES Commercial RealtyNYSE: ACR

Profile

Industry:

Mortgage

Country:

United States

IPO:

07 February 2006

Next earnings report:

N/A

Last dividends:

30 December 2019

Next dividends:

N/A
$121.17 M
-18%vs. 3y high
16%vs. sector
-52%vs. 3y high
28%vs. sector
-17%vs. 3y high
9%vs. sector
-67%vs. 3y high
21%vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$15.39+$0.09(+0.59%)

Dividend

No data over the past 3 years
$20.94 M$21.08 M
$20.94 M$6.46 M

Analysts recommendations

Institutional Ownership

ACR Latest News

ACRES Commercial (ACR) Lags Q3 Earnings and Revenue Estimates
zacks.com30 October 2024 Sentiment: NEGATIVE

ACRES Commercial (ACR) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.73 per share a year ago.

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
prnewswire.com25 October 2024 Sentiment: POSITIVE

CARMIEL, Israel , Oct. 25, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that data from the phase I clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate in development for the treatment of uncontrolled gout, will be presented in a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2024, being held November 14-19, 2024 at the Walter E. Washington Convention Center in Washington, D.C.

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
globenewswire.com11 October 2024 Sentiment: POSITIVE

- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
globenewswire.com09 October 2024 Sentiment: POSITIVE

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix's proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader discovered in collaboration with Gilead Sciences and also in IND-enabling studies, in two posters at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C.

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
globenewswire.com25 September 2024 Sentiment: POSITIVE

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –

ACRES Commercial Realty: Will The Dividend Be Reinstated?
seekingalpha.com19 September 2024 Sentiment: POSITIVE

ACRES Commercial Realty is trading for 66 cents on the dollar. The mREIT continues to buy back shares and has $4.1 million outstanding on its buyback program. CECL reserve and the CRE loan portfolio risk rating were both up sequentially.

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
seekingalpha.com18 September 2024 Sentiment: POSITIVE

Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon's robust pipeline, including the accelerated development of ACR-2316, and a strong cash position, highlight its commitment to advancing innovative cancer therapies. Despite being pre-revenue and operating at a loss due to high R&D expenses, ACRV maintains a healthy cash balance, crucial for ongoing operations and development.

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock
prnewswire.com17 September 2024 Sentiment: POSITIVE

UNIONDALE, N.Y. , Sept. 17, 2024 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
globenewswire.com14 September 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today presented additional positive clinical data at ESMO from the ongoing registrational intent, multicenter Phase 2 trial of ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. The company has also disclosed that the Investigational New Drug (IND) application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024.

ACRES Commercial Realty Corp. (ACR) Q2 2024 Earnings Call Transcript
seekingalpha.com03 August 2024 Sentiment: NEUTRAL

ACRES Commercial Realty Corp. (NYSE:ACR ) Q2 2024 Earnings Call Transcript August 1, 2024 10:00 AM ET Company Participants Kyle Brengel - VP of Operations Mark Fogel - President and CEO Eldron Blackwell - CFO Andrew Fentress - Chairman Conference Call Participants Stephen Laws - Raymond James Chris Muller - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2024 ACRES Commercial Realty Corp. Earnings Conference Call. Currently, all participants are in a listen-only mode.

  • 1(current)
  • 2

What type of business is ACRES Commercial Realty?

ACRES Commercial Realty Corp., a real estate investment trust (REIT), focuses on the origination, holding, and management of commercial real estate mortgage loans and equity investments in commercial real estate property in the United States. It invests in commercial real estate-related assets, including floating-rate first mortgage loans, first priority interests in first mortgage loans, subordinated interests in first mortgage loans, mezzanine financing, preferred equity investments, and commercial mortgage-backed securities. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Exantas Capital Corp. and changed its name to ACRES Commercial Realty Corp. in February 2021. ACRES Commercial Realty Corp. was incorporated in 2005 and is based in Uniondale, New York.

What sector is ACRES Commercial Realty in?

ACRES Commercial Realty is in the Real Estate sector

What industry is ACRES Commercial Realty in?

ACRES Commercial Realty is in the Mortgage industry

What country is ACRES Commercial Realty from?

ACRES Commercial Realty is headquartered in United States

When did ACRES Commercial Realty go public?

ACRES Commercial Realty initial public offering (IPO) was on 07 February 2006

What is ACRES Commercial Realty website?

https://www.acresreit.com

Is ACRES Commercial Realty in the S&P 500?

No, ACRES Commercial Realty is not included in the S&P 500 index

Is ACRES Commercial Realty in the NASDAQ 100?

No, ACRES Commercial Realty is not included in the NASDAQ 100 index

Is ACRES Commercial Realty in the Dow Jones?

No, ACRES Commercial Realty is not included in the Dow Jones index

When was ACRES Commercial Realty the previous earnings report?

No data

When does ACRES Commercial Realty earnings report?

Next earnings report date is not announced yet